Seres Therapeutics, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from 2016 to 2020

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Seres Therapeutics, Inc. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from 2016 to 2020.
  • Seres Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending March 31, 2023 was -$68.2M, a 156% decline year-over-year.
  • Seres Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2020 was $50.9M.
  • Seres Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2019 was -$20.8M, a 142% decline from 2018.
  • Seres Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2018 was $49.7M.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2020 $50.9M +$71.7M Jan 1, 2020 Dec 31, 2020 10-K 2021-03-02
2019 -$20.8M -$70.5M -142% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-02
2018 $49.7M +$69.5M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-02
2017 -$19.7M -$205K -1.05% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$19.5M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.